Differing Expression of Cytokines and Tumor Markers in Combined Pulmonary Fibrosis and Emphysema Compared to Emphysema and Pulmonary Fibrosis

References

• Wiggins J, Strickland B, Turner-Warwick M. Combined cryptogenic fibrosing alveolitis and emphysema: the value of high resolution computed tomography in assessment. Respir. Med. 1990; 84(5):365–9.
   PubMed Web of Science ®Google Scholar
• Cottin V, Nunes H, Brillet PY, Delaval P, Devouassoux G, Tillie-Leblond I, et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur. Respir. J. 2005; 26(4):586–93.
   PubMed Web of Science ®Google Scholar
• Kim JY, Choeng HC, Ahn C, Cho SH. Early and late changes of MMP-2 and MMP-9 in bleomycin-induced pulmonary fibrosis. Yonsei Med. J. 2009; 50(1):68–77.
   PubMed Web of Science ®Google Scholar
• Gansner JM, Rosas IO. Telomeres in lung disease. Transl. Res. 2013; 162(6):343–52.
   PubMed Web of Science ®Google Scholar
• Liu T, Chung MJ, Ullenbruch M, Yu H, Jin H, Hu B, et al. Telomerase activity is required for bleomycin induced pulmonary fibrosis in mice. J. Clin. Invest. 2007; 117(12):3800–9.
   PubMed Web of Science ®Google Scholar
• Le Saux CJ, Davy P, Brampton C, Ahuja SS, Fauce S, Shivshankar P, et al. A novel telomerase activator suppresses lung damage in a murine model of idiopathic pulmonary fibrosis. PLoS One 2013; 8(3):e58423.
   Google Scholar
• Königshoff M, Kneidinger N, Eickelberg O. TGF-β signalling in COPD: deciphering genetic and cellular susceptibilities for future therapeutic regimens. Swiss Med. Wkly. 2009; 139(39–40):554–63.
   PubMed Web of Science ®Google Scholar
• Lee CG, Cho S, Homer RJ, Elias JA. Genetic control of transforming growth factor-β1-induced emphysema and fibrosis in the murine lung. Proc. Am. Thorac. Soc. 2006; 3(6):476–7.
   PubMedGoogle Scholar
• Kanazawa H, Hirata K, Yoshikawa J. Imbalance between vascular endothelial growth factor and endostatin in emphysema. Eur. Respir. J. 2003; 22(4):609–12.
   PubMed Web of Science ®Google Scholar
• Kasahara Y, Tuder RM, Cool CD, Lynch DA, Flores SC, Voelkel NF. Endothelial cell death and decreased expression of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in emphysema. Am. J. Respir. Crit. Care Med. 2001; 163(3 Pt 1):737–44.
   PubMed Web of Science ®Google Scholar
• Ou XM, Li WC, Liu DS, Li YP, Wen FQ, Feng YL, et al. VEGFR-2 antagonist SU5416 attenuates bleomycin-induced pulmonary fibrosis in mice. Int. Immunopharmacol. 2009; 9(1):70–9.
   PubMed Web of Science ®Google Scholar
• Stockmann C, Kerdiles Y, Nomaksteinsky M, Weidemann A, Takeda N, Doedens A, et al. Loss of myeloid cell-derived vascular endothelial growth factor accelerates fibrosis. Proc. Natl. Acad. Sci. U S A. 2010; 107(9):4329–34.
   PubMed Web of Science ®Google Scholar
• Kohno N, Kyoizumi S, Awaya Y, Fukuhara H, Yamakido M, Akiyama M. New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6. Chest 1989; 96(1):68–73.
   Google Scholar
• Iyonaga K, Miyajima M, Suga M, Saita N, Ando M. Alterations in cytokeratin expression by the alveolar lining epithelial cells in lung tissues from patients with idiopathic pulmonary fibrosis. J. Pathol. 1997; 182(2):217–24.
   PubMed Web of Science ®Google Scholar
• Calabrese F, Lunardi F, Giacometti C, Marulli G, Gnoato M, Pontisso P, et al. Overexpression of squamous cell carcinoma antigen in idiopathic pulmonary fibrosis: clinicopathological correlations. Thorax 2008; 63(9):795–802.
   PubMed Web of Science ®Google Scholar
• Kobayashi J, Kitamura S. KL-6: a serum marker for interstitial pneumonia. Chest 1995; 108(2):311–5.
   PubMed Web of Science ®Google Scholar
• Yokoyama A, Kondo K, Nakajima M, Matsushima T, Takahashi T, Nishimura M, et al. Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis. Respirology 2006; 11(2):164–8.
   PubMed Web of Science ®Google Scholar
• Dobashi N, Fujita J, Ohtsuki Y, Yamadori I, Yoshinouchi T, Kamei T, et al. Elevated serum and BAL cytokeratin 19 fragment in pulmonary fibrosis and acute interstitial pneumonia. Eur. Respir. J. 1999; 14(3):574–8.
   PubMed Web of Science ®Google Scholar
• Xu L, Bian W, Gu J, Yang DR, Rong ZH, Shen C. Clinical significance of tumour markers in idiopathic pulmonary fibrosis. J. Clin. Pulm. Med. 2013; 18(10):1865–7. [ Article in Chinese].
   Google Scholar
• Ito M, Hanaoka M, Droma Y, Hatayama O, Sato E, Katsuyama Y, et al. The association of transforming growth factor beta 1 gene polymorphisms with the emphysema phenotype of COPD in Japanese. Intern. Med. 2008; 47(15):1387–94.
   PubMed Web of Science ®Google Scholar
• Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al.. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 2011; 183(6):788–824.
   PubMed Web of Science ®Google Scholar
• Kratzer A, Salys J, Nold-Petry C, Cool C, Zamora M, Bowler R, et al. Role of IL-18 in second-hand smoke–induced emphysema. Am. J. Respir. Cell Mol. Biol. 2013; 48(6):725–32.
   PubMed Web of Science ®Google Scholar
• Kasahara Y, Tuder RM, Taraseviciene-Stewart L, Le Cras TD, Abman S, Hirth PK, et al. Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J. Clin. Invest. 2000; 106(11):1311–9.
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Izumi Y, Kohno M, Ikeda E, Nomori H. Airway administration of vascular endothelial growth factor siRNAs induces transient airspace enlargement in mice. Int. J. Med. Sci. 2013; 10(12):1702–14.
   PubMed Web of Science ®Google Scholar
• Mura M, Binnie M, Han B, Li C, Andrade CF, Shiozaki A, et al. Functions of type II pneumocyte-derived vascular endothelial growth factor in alveolar structure, acute inflammation, and vascular permeability. Am. J. Pathol. 2010; 176(4):1725–34.
   PubMed Web of Science ®Google Scholar
• Chen YB, Lan YW, Chen LG, Huang TT, Choo KB, Cheng WT, et al. Mesenchymal stem cell-based HSP70 promoter-driven VEGFA induction by resveratrol alleviates elastase-induced emphysema in a mouse model. Cell Stress Chaperones. 2015; 20(6):979–89.
   PubMed Web of Science ®Google Scholar
• Roberts JR, Perkins GD, Fujisawa T, Pettigrew KA, Gao F, Ahmed A, et al. Vascular endothelial growth factor promotes physical wound repair and is anti-apoptotic in primary distal lung epithelial and A549 cells. Crit. Care Med. 2007; 35(9):2164–70.
   PubMed Web of Science ®Google Scholar
• Hamada N, Kuwano K, Yamada M, Hagimoto N, Hiasa K, Egashira K, et al. Anti-vascular endothelial growth factor gene therapy attenuates lung injury and fibrosis in mice. J. Immunol. 2005; 175(2):1224–31.
   PubMed Web of Science ®Google Scholar
• Ando M, Miyazaki E, Ito T, Hiroshige S, Nureki SI, Ueno T, et al. Significance of serum vascular endothelial growth factor level in patients with idiopathic pulmonary fibrosis. Lung 2010; 188(3):247–52.
   PubMed Web of Science ®Google Scholar
• Farkas L, Farkas D, Ask K, Möller A, Gauldie J, Margetts P, et al. VEGF ameliorates pulmonary hypertension through inhibition of endothelial apoptosis in experimental lung fibrosis in rats. J. Clin. Invest. 2009; 119(5):1298–311.
   PubMed Web of Science ®Google Scholar
• Bergeron A, Soler P, Kambouchner M, Loiseau P, Milleron B, Valeyre D, et al. Cytokine profiles in idiopathic pulmonary fibrosis suggest an important role for TGF-beta and IL-10. Eur. Respir. J. 2003; 22(1):69–76.
   PubMed Web of Science ®Google Scholar
• Xu L, Yang D, Zhu S, Gu J, Ding F, Bian W, et al. Bleomycin-induced pulmonary fibrosis is attenuated by an antibody against KL-6. Exp. Lung Res. 2013; 39(6):241–8.
   PubMed Web of Science ®Google Scholar
• Sime PJ, Xing Z, Graham FL, Csaky KG, Gauldie J. Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung. J. Clin. Invest. 1997; 100(4):768–76.
   PubMed Web of Science ®Google Scholar
• Kamio K, Ishii T, Motegi T, Hattori K, Kusunoki Y, Azuma A, et al. Decreased serum transforming growth factor-b1 concentration with aging is associated with the severity of emphysema in chronic obstructive pulmonary disease. Geriatr. Gerontol. Int. 2013; 13(4):1069–75.
   PubMed Web of Science ®Google Scholar
• Horowitz JC, Martinez FJ, Thannickal VJ. Mesenchymal cell fate and phenotypes in the pathogenesis of emphysema. COPD 2009; 6(3):201–10.
   PubMedGoogle Scholar
• Morris DG, Huang X, Kaminski N, Wang Y, Shapiro SD, Dolganov G, et al. Loss of integrin alpha(v)beta6-mediated TGF-beta activation causes MMP12-dependent emphysema. Nature 2003; 422(6928):169–73.
   PubMed Web of Science ®Google Scholar
• Samukawa T, Hamada T, Uto H, Yanagi M, Tsukuya G, Nosaki T, et al. The elevation of serum napsin A in idiopathic pulmonary fibrosis, compared with KL-6, surfactant protein-A and surfactant protein-D. BMC Pulm. Med. 2012; 12:55.
   PubMed Web of Science ®Google Scholar
• Ohshimo S, Ishikawa N, Horimasu Y, Hattori N, Hirohashi N, Tanigawa K, et al. Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosis. Respir. Med. 2014; 108(7):1031–9.
   PubMed Web of Science ®Google Scholar
• Ohshimo S, Yokoyama A, Hattori N, Ishikawa N, Hirasawa Y, Kohno N. KL-6, a human MUC1 mucin, promotes proliferation and survival of lung fibroblasts. Biochem. Biophys. Res. Commun. 2005; 338(4):1845–52.
   PubMed Web of Science ®Google Scholar
• Xu L, Yan DR, Zhu SL, Gu J, Bian W, Rong ZH, et al. KL-6 regulated the expression of HGF, collagen and myofibroblast differentiation. Eur. Rev. Med. Pharmacol. Sci. 2013; 17(22):3073–7.
   PubMed Web of Science ®Google Scholar
• Kokuho N, Ishii T, Kamio K, Hayashi H, Kurahara M, Hattori K, et al. Diagnostic values for club cell secretory protein (CC16) in serum of patients of combined pulmonary fibrosis and emphysema. COPD 2015; 12(4):347–54.
   PubMedGoogle Scholar
• Boschetto P, Quintavalle S, Zeni E, Leprotti S, Potena A, Ballerin L, et al. Association between markers of emphysema and more severe chronic obstructive pulmonary disease. Thorax 2006; 61(12):1037–42.
   PubMed Web of Science ®Google Scholar
• D'Armiento JM, Goldklang MP, Hardigan AA, Geraghty P, Roth MD, Connett JE, et al. Increased matrix metalloproteinase (MMPs) levels do not predict disease severity or progression in emphysema. PLoS One 2013; 8(2):e56352.
   Google Scholar
• Foronjy R, Nkyimbeng T, Wallace A, Thankachen J, Okada Y, Lemaitre V, et al. Transgenic expression of matrix metalloproteinase-9 causes adult-onset emphysema in mice associated with the loss of alveolar elastin. Am. J. Physiol. Lung Cell Mol. Physiol. 2008; 294(6):L1149–57.
   Google Scholar
• Atkinson JJ, Lutey BA, Suzuki Y, Toennies HM, Kelley DG, Kobayashi DK, et al. The role of matrix metalloproteinase-9 in cigarette smoke–induced emphysema. Am. J. Respir. Crit. Care Med. 2011; 183(7):876–84.
   PubMed Web of Science ®Google Scholar
• Cabrera S, Gaxiola M, Arreola JL, Ramírez R, Jara P, D'Armiento J, et al. Overexpression of MMP9 in macrophages attenuates pulmonary fibrosis induced by bleomycin. Int. J. Biochem. Cell Biol. 2007; 39(12):2324–38.
   PubMed Web of Science ®Google Scholar
• Jin X, Dai H, Ding K, Xu X, Pang B, Wang C. Rapamycin attenuates bleomycin-induced pulmonary fibrosis in rats and the expression of metalloproteinase-9 and tissue inhibitors of metalloproteinase-1 in lung tissue. Chin. Med. J. 2014; 127(7):1304–9.
   PubMed Web of Science ®Google Scholar
• Alder JK, Guo N, Kembou F, Parry EM, Anderson CJ, Gorgy AI, et al. Telomere length is a determinant of emphysema susceptibility. Am. J. Respir. Crit. Care Med. 2011; 184(8):904–12.
   PubMed Web of Science ®Google Scholar
• Diaz de Leon A, Cronkhite JT, Katzenstein AL, Godwin JD, Raghu G, Glazer CS, et al. Telomere lengths, pulmonary fibrosis and telomerase (TERT) mutations. PLoS One 2010; 5(5):e10680.
   PubMed Web of Science ®Google Scholar